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Background: Harpalycin 2 (HP-2) is an isoflavone isolated from the leaves of Harpalyce brasiliana Benth., a
snakeroot found in northeast region of Brazil and used in folk medicine to treat snakebite. Its leaves are said to be
anti-inflammatory. Secretory phospholipases A2 are important toxins found in snake venom and are structurally
related to those found in inflammatory conditions in mammals, as in arthritis and atherosclerosis, and for this
reason can be valuable tools for searching new anti-phospholipase A2 drugs.
Methods: HP-2 and piratoxin-III (PrTX-III) were purified through chromatographic techniques. The effect of HP-2 in
the enzymatic activity of PrTX-III was carried out using 4-nitro-3-octanoyloxy-benzoic acid as the substrate. PrTX-III
induced platelet aggregation was inhibited by HP-2 when compared to aristolochic acid and p-bromophenacyl
bromide (p-BPB). In an attempt to elucidate how HP-2 interacts with PrTX-III, mass spectrometry, circular dichroism
and intrinsic fluorescence analysis were performed. Docking scores of the ligands (HP-2, aristolochic acid and p-BPB)
using PrTX-III as target were also calculated.
Results: HP-2 inhibited the enzymatic activity of PrTX-III (IC50 11.34 ± 0.28 μg/mL) although it did not form a stable
chemical complex in the active site, since mass spectrometry measurements showed no difference between native
(13,837.34 Da) and HP-2 treated PrTX-III (13,856.12 Da). A structural analysis of PrTX-III after treatment with HP-2
showed a decrease in dimerization and a slight protein unfolding. In the platelet aggregation assay, HP-2 previously
incubated with PrTX-III inhibited the aggregation when compared with untreated protein. PrTX-III chemical treated
with aristolochic acid and p-BPB, two standard PLA2 inhibitors, showed low inhibitory effects when compared with
the HP-2 treatment. Docking scores corroborated these results, showing higher affinity of HP-2 for the PrTX-III target
(PDB code: 1GMZ) than aristolochic acid and p-BPB. HP-2 previous incubated with the platelets inhibits the
aggregation induced by untreated PrTX-III as well as arachidonic acid.
Conclusion: HP-2 changes the structure of PrTX-III, inhibiting the enzymatic activity of this enzyme. In addition,
PrTX-III platelet aggregant activity was inhibited by treatment with HP-2, p-BPB and aristolochic acid, and these
results were corroborated by docking scores.
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Medicinal plants have been used in traditional medicine as
an alternative and supplementary therapy to treat snakebite
poisoning, and many other health problems, such as in-
flammatory disorders [1]. In 1982, Nakagawa et al. [2]
tested the anti-ophidian activity of “Específico Pessoa”, a
Brazilian phytotherapic tincture used in folk medicine to
treat snakebite, mainly in the Amazon region. Two preny-
lated pterocarpans, the cabenegrins A-I and A-II, had been
pointed out as responsible for this activity. Several years
later, the same compounds were found in Harpalyce
brasiliana Benth (Papilionoideae), popularly known in the
Northeast of Brazil as “raiz-de-cobra” (Port. Lit.: snake-
root). Its roots have been used to treat snakebite [3], while
its leaves are claimed to be anti-inflammatory [Personal
ethnopharmacological survey].
Secretory phospholipases A2 (sPLA2) are present in most
snake venoms and show important neurotoxic and myo-
toxic activities, and most of them are not fully neutralized
by commercial antivenom sera [4]. Flavonoids exhibit dif-
ferent inhibitory levels in group I sPLA2s from porcine
pancreas and Naja naja venom, and in group II sPLA2s
from Vipera russelii and Crotalus atrox venoms. The most
important regions involved in the inhibition of sPLA2 have
been reported to be the hydroxyl groups at 30- and 40-
positions [5,6]. Iglesias et al. [7] showed that flavonoids
such as morin can modify the secondary structure of the
snake venom sPLA2. Toyama et al. [8] showed that 7-
hydroxycoumarin interacts with sPLA2 and causes some
structural modifications, indicating its potential use to sup-
press inflammation induced by sPLA2.
Group II sPLA2 enzymes have been found in inflamma-
tory sites in animal models, as well as in synovial fluids
from patients with rheumatoid arthritis and a number of
inflammatory diseases, in which, a correlation between
serum sPLA2 levels and disease activity has been observed
[9,10]. Exogenous administration of sPLA2, such as snake
venom sPLA2, induces and/or exacerbates inflammatory
response in animals [11,12]. Structural analyses revealed
that snake venom sPLA2s have a similar molecular profile
to those of human secretory PLA2s as well as a conserved
catalytic site [13], thus making them useful tools for the
search of new anti-phospholipase A2 drugs.
Pterocarpans have been pointed out as possible com-
pounds involved in snakebite protection of “Específico Pes-
soa”. These molecules are characterized as a group of
isoflavonoids formed from isoflavones. Here, the anti-
phospholipasic activity of harpalycin 2 (HP-2), an isofla-
vone isolated from the leaves of Harpalyce brasiliana
Benth., against PrTX-III was investigated. Aristolochic acid
and p-bromophenacyl bromide were used as gold stan-
dards sPLA2 inhibitors. PrTX-III is a catalytically active,
hemolytic and platelet aggregant D49 sPLA2, isolated from
the Bothrops pirajai venom [14].Methods
Venom
Bothrops pirajai venom was purchased from Bio-Agents
Serpentarium in the city of Batatais (São Paulo, Brazil).
Plant material
Leaves of Harpalyce brasiliana Benth. were collected at
the Chapada do Araripe, Barbalha (Ceará, Brazil) by Prof.
Edilberto Rocha Silveira. Botanical authentication was
made by Prof. Edson P. Nunes of the Department of Biol-
ogy, Federal University of Ceará. Voucher specimen (num-
ber: 32 525) has been deposited at the Prisco Bezerra
Herbarium (EAC), Department de Biology, Federal Univer-
sity of Ceará, Fortaleza (Ceará, Brazil).
General procedures
The mass spectra were obtained on a Hewlett-Packard
5971 mass spectrometer by electron impact ionization
(70 eV). 1H and 13C NMR spectra were recorded on a Bru-
ker Avance DRX-500 (500 MHz for 1 H and 125 MHz for
13C); chemical shifts were expressedin scale and were
referenced to residual DMSO (2.5 and 39.5 ppm). Silica
Gel 60 (Merck, 70–230 mesh) was used for analytical TLC.
Column chromatographies were performed over silica gel
(Merck, 60 F254 230–400 mesh).
Extraction and isolation of harpalycin 2
Leaves of Harpalyce brasiliana were pulverized and
extracted with EtOH at room temperature. The solvent was
removed under reduced pressure which produced a dark
viscous extract (HBFE). Liquid-liquid partition of a water
suspension of HBFE (110 g) using petrol ether, CHCl3,
EtOAc and n-BuOH yielded five fractions after solvent evap-
oration or lyophilization: HBFEEp (24.5 g), HBFEC (22.4 g),
HBFEA (6.8 g), HBFEB (30.4 g) and HBFEAq (21.2 g).
Flash chromatography of HBFEC (12.0 g) using n-hexane
and EtOAc as binary mixtures of increasing polarity
afforded 30 fractions, which were pooled in 9 fractions after
thin layer chromatography (TLC) analysis. HBFEC (10–12)
presented a yellow precipitate, yielding 120.0 mg of a white
amorphous solid (m.p. 206.9-208.9°C). Spectrometric ana-
lysis showed the structure of the isoflavone harpalycin 2.
The fractions HBFEC (8–9) and HBFEC (13–17) were
purified, using the same method, yielding more 200.0 mg
of harpalycin 2 (HP-2).
Purification of PrTX-III
Bothrops pirajai venom was first fractioned in two con-
secutive chromatographic steps as described by Toyama
et al. [15]. Approximately 20 mg of the lyophilized venom
was dissolved in 250 μL of 0.05 M ammonium bicarbonate,
pH 7.8 (Buffer A). After homogenization, venom solution
was clarified by centrifugation at 10,000 rpm for 3 min.
The supernatant was inserted into a Protein Pack SP 5PW
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linear gradient of concentration between 0.05 and 1.0 M
ammonium bicarbonate with 750 μL of 0.1% (v/v) trifluor-
oacetic acid (Buffer B). The fractions were collected, lyo-
philized and clarified by centrifugation and the supernatant
inserted into a μ-Bondapack C18 column (0.78 cm x
30 cm) (Waters 991-PDA system). Elution of peaks pro-
ceeded with a linear gradient between 0% and 66.5% (v/v)
acetonitrile (solvent B) in 0.1% (v/v) trifluoroacetic acid, at
a flow rate of 2.0 mL/min. Absorbances were monitored at
280 nm. Fractions were collected, lyophilized and stored
at −20°C. The PrTX-III fraction was identified by the re-
tention time and the measurement of the catalytic activity
(since PrTX-III is the activity isoform of B. pirajai venom).
The purity degree of PrTX-III was evaluated by Tricine
SDS-PAGE and by mass spectrometry on a MALDI-TOF
mass spectrometer, as previously described [12,16].
Measurement of sPLA2 activity
sPLA2 activity was measured following the protocols
described by Lee et al. [13] and modified by Toyama et al.
[12] for 96-well plate, using 4-nitro-3-octanoyloxy-benzoic
acid (4N3OBA, manufactured by BIOMOL, USA) as the sub-
strate. Enzyme activity was calculated based on the increase
in absorbance after 20 min. All assays were performed using
n=12 and absorbances at 425 nm were measured using a
SpectraMax 340 multiwell plate reader (Molecular Devices,
Sunnyvale, CA). After the addition of sPLA2 (20 μg), the reac-
tion mixture was incubated for 40 min at 37°C, and the ab-
sorbance read at 10 min intervals. For the estimation of the
IC50 of harpalycin 2 for PrTX-III, different concentrations of
HP-2 (5, 10, 20, 40 and 80 μg) were added to each well. The
remaining enzymatic assay was conducted as described above.
Harpalycin 2 was previously dissolved in DMSO 1%.
Incubation of sPLA2 with harpalycin 2 and purification of HP-
2 treated sPLA2 (PrTX-III: HP-2) and amino acid analysis
The incubation of sPLA2 with HP-2 (w: w; 4:1), followed
the procedures described by Iglesias et al. [7]. Briefly, HP-2
was dissolved in DMSO 1%. 250 μL of HP-2 solution was
added to 1,000 μL of homogenized solution of PrTX-III.
The mixed solution was incubated for 60 min in a water
bath at 37°C. Samples of 200 μL of this mixture were loaded
into a preparative reverse phase HPLC column to separate
the treated enzyme (PrTX-III: HP-2) from HP-2. After col-
umn equilibration with buffer A (aqueous solution of 0.1%
TFA), samples were eluted using a discontinuous gradient
of buffer B (66.6% of acetonitrile in 0.1% TFA) at a constant
flow rate of 2.0 mL/min. The chromatographic run was
monitored at 214 nm for detection of PrTX-III, PrTX-III:
HP-2 and HP-2. 1 nmol of purified protein (PrTX-III or
PrTX-III: HP-2) was hydrolyzed with 6 N HCl (200 μL) in
the presence of 10μL of phenol solution for prevention of
unspecific amino acid oxidation. Amino acid hydrolysis wasperformed at 106°C for 24 h. After this time, the excess
HCl was removed and the hydrolyzed amino acids were
rehydrated with a solution of ethanol: water: triethylamine
(v: v; 2:2:1). Post-column derivatization was performed with
an aqueous solution of phenylisothiocyanate (ethanol:
water: triethylamine: phenylisothiocyanate; v: v; 7:1:1:1).
Samples and amino acid standards were derivatized using a
PICO-TAG amino acid analyzer system (Waters, USA).
Molecular exclusion chromatography
A molecular exclusion chromatography was initially per-
formed using an AP-1 column (Waters, 1x60 cm) previous
packed with Superdex 75 (GE Healthcare Pharmacia) as pre-
viously described by Oliveira et al. [17]. For molecular exclu-
sion chromatography of the PrTX-III and PrTX-III: HP-2 as
well as the protein marker, 1 mg of the protein sample was
dissolved in the same buffer used for equilibration of the
chromatographic column and sample elution (Potassium
phosphate buffer 0.05 M, pH 7.5). Samples were dissolved in
250 μL of this buffer and then centrifuged at 4,500 g for
5 minutes. 200 μL of supernatant was recovered and taken
at 37°C for 60 minutes before injection into the column.
Injections of 25 μL of each sample were carried out through
the column; and elution of fractions was performed under
isocratic condition with constant flow rate of 0.2 mL/min
and monitored at 280 nm.
Mass spectrometry
The molecular mass of PrTX-III and PrTX-III: HP-2 were
determined by matrix-assisted laser desorption ionization-
time-of-flight (MALDI-TOF) mass spectrometry using a
Voyager-DE PRO MALDI-TOF mass spectrometer (Applied
BiosystemsW, Life TechnologiesTM, USA). One microliter of
samples (PrTX-III and PrTX-III: HP-2) in 0.1% TFA was
mixed with 2 μL of the matrix a-cyano-4-hydroxycinnamic
acid, 50% acetonitrile, and 0.1% TFA (v/v). The matrix was
prepared with 30% acetonitrile and 0.1% TFA (v/v). The
equipment conditions were as follows: accelerating voltage of
25 kV, laser fixed at 2,890 μJ/com2, delay of 300 ns and lin-
ear analysis mode.
Circular dichroism spectroscopy
Purified enzymes - native and HP-2 treated PrTX-III – were
dissolved in a 10 mM sodium phosphate buffer (pH 7.4) and
the final protein concentrations were adjusted to 8.7 mM.
After centrifugation at 4,000 g for 5 min, samples were trans-
ferred to a 1 mm pathlength quartz cuvette. Circular dichro-
ism spectra in the wavelength range of 185–300 nm were
acquired in-house with a J720 spectropolarimeter (Jasco©,
Japan) using a bandwidth of 1 nm and a response time of
1 s. Data collection was performed at room temperature
with a scanning speed of 100 nm/min. Nine scans were
taken for each sample and all spectra were corrected by
subtraction of buffer blanks.
Figure 1 a. Demonstrates the inhibitory effect induced by p-BPB
and HP-2 on the enzymatic activity of PrTX-III in presence of
4-nitro-3-octanoyloxy-benzoic acid as substrate of the enzymatic
reaction. Phospholipasic A2 activity was expressed as Vo at 425 nm.
Each point represents the mean±SEM (n=12) and *p<0.05. b. Shows
the molecular exclusion chromatography of the PrTX-III and PrTX-III
previously treated with HP-2 (PrTX-III: HP-2). Both samples were subjected
to the same chromatographic run conditions. c. Displays the Tricine SDS-
PAGE profile where the MK was the low molecular weight marker.
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The relative intrinsic fluorescence intensity of native PrTX-III
or HP-2 treated PrTX-III (PrTX-III: HP-2) was monitored
with a spectrofluorimeter (Shimadzu©, Japan). 2.0 mL of the
reaction mixtures, consisting of 100 mM Tris–HCl buffer
(pH 7.4), sPLA2 (200 μg/mL) and 5 mM CaCl2, were put into
a 10 mm pathlength quartz cuvette. Fluorescence was mea-
sured at between 300 and 450 nm after excitation at 280 nm.
Platelet aggregation studies
The platelet aggregation activities were conducted as
described by Oliveira et al. [18] and dos Santos et al. [19].
Venous blood was collected with informed consent from
healthy volunteers who formally denied taking any medica-
tion in the previous 14 days. All experiments using human
material were carried out according to Helsinki Declaration
and were approved by the Ethical Committee for Human Re-
search of State University of Campinas under the no.
0323.0.1.146.000-09. Blood was collected by a two-syringe
technique using polypropylene syringes and 19-gauge nee-
dles, and immediately transferred into polypropylene tubes
containing 1/10 of final volume of 3.8% trisodium citrate.
After removing the platelet-rich plasma (PRP), the remaining
blood was prepared by centrifugation at 200 g for 10 min
and the washed platelet solution (WP) was obtained from
the residue by centrifugation of citrated blood at 1,500 g for
20 min. The platelets were left for 1 hour at room
temperature to recover their sensitivity to aggregating agents.
Platelet counts were performed on a Coulter S Plus (Coulter
Electronics, Hialeah, FL) or by phase-contrast microscopy.
Platelet aggregation was carried out using 400 μL of the
washed platelets solution in a cuvette and kept at 37°C with
constant stirring. The desired concentration of protein was
added and 3 minutes after to the addition, the aggregation
was recorded for 5–10 min by using an aggregometer
(Payton Scientific Inc., USA). Aggregation experiments were
performed with 10 μg of PrTX-III and PrTX-III: HP-2.,
PrTX-III: aristolochic acid or PrTX-III: p-bromophenacyl
bromide. In order to elucidate HP-2 mode of action, 10 μL
of HP-2 (5 mg/mL), AACOCF3 (1 mM) and INDO (1 mM)
were added 5 minutes before the addition of native PrTX-III
(10 μg) or arachidonic acid (AA, 50 mM).
Docking studies
The structural optimizations of the harpalycin 2 (HP-2),
aristolochic acid (Aris Ac) and p-bromophenacyl bromide
(p-BPB) ligands were initially achieved using the AM1
method [20] implemented in the BioMedCache program
[21] with default values for the convergence criteria.
Docking calculations were performed with the GOLD 4.0
program [22] to obtain the in silico affinity of the ligands
with respect to the PrTX-III target. The tridimensional
coordinates of the target were taken from the RCSB Pro-
tein Data Bank (PDB), under the PDB code 1GMZ, as adimeric quaternary structure. The “A” chain was chosen
for all the calculations. The docking calculations were per-
formed to consider the flexibility of all the ligands and the
flexibility of the target, in order to represent the induced
fit generated by the presence of non-native ligands, using
the following approach: the residues Phe5, Ile9, Phe18,
Tyr21, Val22, Tyr27, His47, Asp48, Lys60 and Phe96 were
configured in such a way that their side-chain torsions
were considered active during the calculations. The active
site was defined as all the atoms within a radius of 8.0 Å
from the co-crystallized isopropyl alcohol (IPA).
Figure 2 a. Shows the reverse phase HPLC profile of the PrTX-III
and the PrTX-III from the incubation with HP-2. Both samples were
eluted at same chromatographic conditions using a linear
discontinuous increasing of buffer b. The amino acid analysis of
PrTX-III and PrTX-III: HP-2. The amino acid counting was expresses as
number of each amino acid residues found by each mol of protein.
Figure 3 a. Displays the CD spectra of native PrTX-III and
PrTX-III treated with HP-2. Data over the range 185–260 nm is
shown and CD spectra are expressed in theta machine units in
millidegrees. b. Shows the fluorescence curves of untreated sPLA2
(PrTX-III) and HP-2 treated sPLA2 (PrTX-III: HP-2).
Ximenes et al. BMC Complementary and Alternative Medicine 2012, 12:139 Page 5 of 10
http://www.biomedcentral.com/1472-6882/12/139Statistical analysis
Results were expressed as mean±S.E.M. and analyzed by
ANOVA followed by Dunnett’s test using GraphPad
PrismW 5.0 with significance set at p < 0.05*.
Results
Harpalycin 2 (HP-2) was isolated as a white amorphous
solid with m.p. 232.6-234.4°C. Its molecular formula of
C21H18O7 was established by the molecular ion at m/z 382
Daltons in the MS spectrum. Structure elucidation was per-
formed by spectroscopic means, including 1D and 2D
NMR, and comparison with the data from literature [3].
Harpalycin 2 (HP-2) showed a potent inhibitory capacity
when compared to the classical sPLA2 inhibitor p-
bromophenacyl bromide (p-BPB), with an IC50 calculated at
11.34±0.28 μg per well, whereas p-BPB showed only a mar-
ginal inhibition of PrTX-III catalytic active (Figure 1a). Theisolation of PrTX-III yielded 15% (w: w). Native PrTX-III
subjected to molecular mass exclusion chromatography
showed the presence of a main fraction with a molecular
mass that was estimated at 25,000 Da and a minor fraction
with molecular mass estimated at 14,000 Da. The chromato-
graphic profile of PrTX-III: HP-2 revealed the presence of a
main fraction, which had its molecular mass estimated at
14,000 Da, and a minor fraction with molecular mass of
20,000 Da. According to our data, the main fraction eluted
from the sample of PrTX-III: HP-2 represented approxi-
mately 90% of the total. These results showed that HP-2
treatment of PrTX-III induced a reduction of the
dimerization of PrTX-III, while the native PrTX-III showed
a typical transition from the monomer to dimmer
(Figure 1b). The chromatographic results were also corrobo-
rated using a Tricine SDS-PAGE analysis (Figure 1c).
Figure 4 Aggregation assays were performed using a protein concentration of 10 μg of native PrTX-III or PrTX-III previously treated
with harpalycin 2 (HP-2), aristolochic acid (Aris Ac) or p-bromophenacyl bromide (p-BPB) (a). The effect of previous incubation of platelets
with HP-2 before the administration of PrTX-III or arachidonic acid is showed in (c). Previous incubation with AACOCF3 or INDO before the
administration of PrTX-III is showed in (e). (b), (d) and (f) demonstrate the platelet aggregation results after 8 minutes of experimental condition
and each point in the respective table represent the mean± SEM (n = 4) and *p < 0.05.
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cated that sPLA2 fraction was eluted at 31.7 minutes
whereas PrTX-III: HP-2 was eluted at 32.3 minutes, show-
ing a discreet shift in the retention time of this protein
(Figure 2a). The amino acid analysis of native and PrTX-III
previously treated with HP-2 did not revealed changes in
the amino acid amount in both samples (Figure 2b). Mass
spectrometry data from the native PrTX-III and PrTX-III:
HP-2 showed masses of 13,750.3 Da and 13,736.2 Da,respectively. These results suggest that binding of the HP-2
with PrTX-III did not involve the formation of stable com-
plexes. The discrepancy between results from the amino
acid analysis and spectrometric studies is probably due to
the presence of HCl 6 N used for rupturing the amino acid
bond that could revert the acid condition of some amino
acids or restore the H+ lost in the reaction with HP-2 with
PrTX-III. This is true for the PICO-TAG amino acid ana-
lysis based in the post column derivatization and the final
Figure 5 Superposition of the best docking solution for the ligands harpalycin 2, aristolochic acid and p-bromophenacyl bromide
(stick models in orange, red and green colors, respectively). The co-crystallized isopropyl alcohol (IPA) is showed as a gray ball model. The
hydrogen atoms were omitted for clarity reasons.
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from Gln.
The CD spectra of the PrTX-III: HP-2 showed an evident
decrease of total alpha-helix as well as an increase of beta-
sheets when compared with the spectra of native PrTX-III,
suggesting a partial unfolding of the protein induced by
HP-2 treatment (Figure 3a). This data was reinforced by
the increase in the tryptophan fluorescence of the treated
protein as seen in Figure 3b.
The platelet aggregation observed for native PrTX-III
was blocked by treatment of PrTX-III with HP-2, and par-
tially inhibited by the treatment with aristolochic acid (ArisFigure 6 Detailed view of the best docking solution for the harpalyci
hydrogen atoms were omitted for clarity reasons.Ac) p-BPB (Figure 4a). Figure 4a also shows that the
PrTX-III treated with HP-2 was able to trigger an initial
platelet aggregation of approximately 20%, which was rap-
idly reverted. This effect was not very evident for the treat-
ment of PrTX-III with aristolochic acid. HP-2 previously
added to the platelets inhibited the aggregating effect
induced by arachidonic acid as well as the effect induced
by PrTX-III (Figure 4b). The effect of HP-2 was similar
that of AAOCF3 (arachidonyl trifluoromethyl ketone), a
specific PLA2 inhibitor. Previous treatment with indometh-
acin only partially inhibited the aggregation induced by
PrTX-III (Figure 4c), showing that the phospholipase A2n 2 ligand. The hydrogen bonds are showed in black lines. The
Table 1 Details of the docking results and the intermolecular interactions identified for the harpalycin 2 (HP-2),
aristolochic acid (Aris Ac) and p-bromophenacyl bromide (p-BPB) ligands with the PrTX-III target
HP-2 Aris Ac p-BPB
inhibition % of platelet aggregation 95 55 35
GOLD score 36.78 35.29 26.63
Residues HB HP HB HP HB HP
LEU2 − yes − − − −
PHE5 − − − yes − yes
ILE9 − − − yes − yes
PRO17 − yes − yes − −
PHE18 − yes − − − −
TYR21 − − − yes − yes
ASP48 2.88 − − − − −
PHE96 − − − yes − yes
The inhibition % of platelet aggregation data was included for comparison reasons.
* HB stands for Hydrogen Bonds and HP for Hydrophobic Interactions.
** All HB distance values are given in Å.
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PLA2 downstream cascade is also involved, which was cor-
roborated by the fact that HP-2 also inhibited arachidonic
acid induced platelet aggregation.
The superposition of the best docking solutions for
the harpalycin 2 (HP-2), aristolochic acid and p-
bromophenacyl bromide ligands can be observed in Figure 5.
The docking scores for these calculations were 36.78, 35.29
and 26.63, respectively, showing a better affinity between the
PrTX-III target and harpalycin 2, in comparison with aristo-
lochic acid and p-bromophenacyl bromide. A detailed in-
spection of the binding mode of HP-2 in PrtX-III can be
found in Figure 6. The molecular reasons for the greater sta-
bility (greater docking score) of the harpalycin 2 ligand in
the active site of the PrTX-III can be explained mainly by
the presence of some important intermolecular interactions,
in particular, a hydrogen bond that harpalycin 2 establishes
with the residue Asp48, with 2.88 Å (see Figure 6). The
detailed comparison between the docking results obtained
for these three ligands can be found in Table 1.
Discussion
Snake venoms are rich sources of phospholipase A2 and
PLA2-homologues, active calcium-binding Asp49 enzymes
and essentially inactive Lys49 proteins, respectively. They
are responsible for multiple pharmacological effects, some
of which are dependent on catalytic activity and others of
which are not. The pharmacological or biological effects that
do not depend on enzymatic activity are driven by other
pharmacological regions or sites that include calcium-
binding loop, beta-wing and C-terminal region [16,19,23,24].
The precise location or mapping of these pharmacological
sites is not easy to find due to the fact that the residues
involved in myotoxicity and neurotoxicity significantly over-
lap, suggesting that multiple biological effects observed inmany snake venom PLA2s are a consequence of superposed
structural determinants on the protein surface [24]. How-
ever, the consensual idea is that enzymatic activity of PLA2
is the major factor responsible for the majority of the
pharmacological activity induced by the PLA2 in snake
venom, such as inflammatory activity, especially due to the
arachidonic acid cleavage [25]. PrTX-III showed a sigmoidal
behavior on the substrate concentration, which implies co-
operation of substrate binding. This effect has been
described for other sPLA2 such as those isolated from
Bothrops jararacussu [26] and Crotalus durissus terrificus
[17] venoms. The transition between the monomers to dim-
mers increases the phospholipasic A2 activity 100 times,
which could explain in part the inhibition of PrTX-III by
HP-2, since the treatment with HP-2 showed an increase of
the monomer form over the dimmeric form.
Crystallographic studies showed that PrTX-III has puta-
tive dimmer interface identified in the crystal lattice which
brings together the calcium-binding loops of neighboring
molecules, along with the C-terminal regions which are di-
sulfide bonded to those loops, thereby offering a possible
route of communication between active sites. The inter-
action of HP-2 with PrTX-III seems to induce a chemical
modification of crucial amino acid residues involved in the
sPLA2 catalysis. It could also modify some important resi-
dues related to the dimmer formation, agreeing in CD
spectra and fluorescence measurement which suggests that
HP-2 induced a partial unfolding of PrTX-III. The N-
terminal region as well as the calcium-binding loop and
the alpha-helix of sPLA2 play an important role for the
sPLA2 catalysis. The modification in these region leads to
an irreversible lost of enzymatic activity of sPLA2 and/or
its ability for binding to cell membrane [27].
PrTX-III induced a platelet aggregation in a dose
dependent manner and this effect was abolished by
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periment, however, we observed a slight aggregation that
was quickly reverted. Previous report by Polgár et al. [28]
suggests that a glycophosphatidylinositol-anchored plate-
let-membrane heparan sulphate proteoglycan is the bind-
ing site for sPLA2 on platelets. Some specific mutation
studies carried out with PLA2 have shown that the binding
of secretory PLA2 to this receptor involves a specific recog-
nition of the CRD region of this receptor, which is located
near the catalytic site of PLA2 and calcium-binding loop
[18]. The binding of HP-2 to the active site of PrTX-III
could interfere with this ability. The HP-2 effect on the
platelet resembles the effect induced by AACOCF3, which
is a selective PLA2 inhibitor, showing a potential anti-
inflammatory effect of harpalycin 2 that could be derived
from PLA2 inhibition. Indomethacin partially inhibited the
aggregating effect of PrTX-III pointing to the role of
cyclooxygenases in this pharmacological action. HP-2
could also being acting in this pathway, since it can block
the platelet aggregating effect induced by arachidonic acid,
which is a step forward in the downstream cascade of
PLA2/COX-1/2/eicosanoids.
These experimental results corroborate with the in silico
observations, where harpalycin 2 ligand presented a greater
affinity for the PrTX-III active site, in comparison with the
two other ligands (aristolochic acid and p-BPB). This trend
implies that the ligands with the best activities have greater
stabilities (high docking scores) within the PrTX-III target
according to the docking results, and the ligands with the
worst activities have weak interactions (low scores) with
the same target. These results suggest that the inhibition of
platelet aggregation is due to the inhibition of the inter-
action between platelet substrate and the sPLA2.
Conclusions
Our results of the harpalycin 2 effect on PrTX-III are im-
portant as they indicate a possible anti-ophidian and anti-
inflammatory activity of this compound and, as well as in
part, corroborate the ethnobotanical use that is described
for H. brasiliana in the Northeast of Brazil. The in silico
results also gave us clues about how these molecules inter-
act in the active site of phospholipases A2 inhibiting their
enzymatic activity.
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